Minimally invasive lung adenocarcinoma

Summary

Minimally invasive lung adenocarcinoma (MONDO:0004991) is a disease and 8 clinical trials. Top therapeutic interventions include erlotinib, pegfilgrastim, and veliparib. A subtype of lung adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	minimally invasive lung adenocarcinoma
Mondo ID	MONDO:0004991
EFO	EFO:0000308
MeSH	D002282
DOID	DOID:4926
NCIT	C2923
SNOMED CT	373627005
UMLS	C0007120
MedGen	2871
GARD	0024141
Is cancer (heuristic)	no

Also known as: BAC · bac · bronchioalveolar adenocarcinoma of lung · bronchioalveolar adenocarcinoma of the lung · bronchioalveolar lung carcinoma · bronchiolo-alveolar carcinoma of lung · bronchiolo-alveolar carcinoma of the lung · bronchiolo-alveolar lung carcinoma · bronchioloalveolar adenocarcinoma of lung · bronchioloalveolar adenocarcinoma of the lung · bronchioloalveolar carcinoma · bronchioloalveolar lung adenocarcinoma · carcinoma, bronchioloalveolar, malignant · minimally invasive lung adenocarcinoma

Data availability: 34 cell lines.

Disease family

This is a subtype of lung adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › lung adenocarcinoma › minimally invasive lung adenocarcinoma

Related subtypes (10): lung adenocarcinoma in situ, lung combined type small cell adenocarcinoma, lung adenoid cystic carcinoma, acinar lung adenocarcinoma, lung occult adenocarcinoma, papillary lung adenocarcinoma, lung signet ring cell carcinoma, well-differentiated fetal adenocarcinoma of the lung, lung colloid adenocarcinoma, solid adenocarcinoma with mucin production

Subtypes (3): mixed mucinous and nonmucinous bronchioloalveolar adenocarcinoma, mucinous bronchioloalveolar adenocarcinoma, nonmucinous bronchioloalveolar adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Gefitinib	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Carboplatin, Erlotinib, Metformin, Paclitaxel.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	7
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00334815	PHASE2	ACTIVE_NOT_RECRUITING	Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT01386385	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT03110978	PHASE2	ACTIVE_NOT_RECRUITING	Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
NCT00126581	PHASE2	COMPLETED	Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
NCT00950365	PHASE2	COMPLETED	Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
NCT01294306	PHASE2	COMPLETED	MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
NCT02186847	PHASE2	COMPLETED	Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ERLOTINIB	4	5
PEGFILGRASTIM	4	1
VELIPARIB	3	2